Literature DB >> 1391952

Thrombotic microangiopathies in the 1980s: clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic.

C E Thompson1, L E Damon, C A Ries, C A Linker.   

Abstract

We reviewed the medical records of 44 adults with 50 consecutive episodes of thrombotic thrombocytopenia purpura (TTP) or hemolytic uremic syndrome (HUS) seen at the University of California, San Francisco affiliated hospitals during the past decade. Patients were treated according to a uniform plan in which initial therapy included daily large volume plasmapheresis using fresh frozen plasma. Patients not responding completely to initial therapy were treated with a salvage regimen including splenectomy, dextran, and corticosteroids. At the time of diagnosis, the lactate dehydrogenase (LDH) was elevated in 98% of cases, with a median value of 1,208 U/L. Other clinical features were present inconsistently, and only 34% of "TTP" episodes involved the classic pentad of hemolytic anemia, thrombocytopenia, neurologic disorders, noninfectious fever, and renal impairment. Primary treatment with plasma exchange produced complete remission in 56% (27 of 48) of the episodes. Previously splenectomized patients uniformly responded to plasma therapy (12 of 12). In patients not responding completely to primary therapy, salvage splenectomy produced complete responses in 81% (13 of 16) of the cases. The pattern of clinical response to therapy was consistent, with initial resolution of neurologic dysfunction (median, 3 days) followed by normalization of LDH levels (5 days) and platelet count (7 days). Normalization of renal function occurred significantly later (15 days). Although short-term responses to plasma therapy in human immunodeficiency virus (HIV)-seropositive patients did not differ from other patients, no HIV-positive patient survived more than 2 years from diagnosis of thrombotic microangiopathy (TMA). We conclude that the diagnosis of TMA requires a high degree of clinical suspicion and that the diagnostic criteria should consist of microangiopathic hemolytic anemia, thrombocytopenia, and an elevated LDH. Initial therapy with plasma exchange leads to disease control in the majority of cases, but an optimal treatment strategy requires the use of alternative methods if initial remission is transient or not achieved. Salvage therapy with splenectomy, steroids, and dextran is highly effective in this setting.

Entities:  

Mesh:

Year:  1992        PMID: 1391952

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

1.  Rituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura--haemolytic uraemic syndrome.

Authors:  Domenica Caramazza; Gerlando Quintini; Ignazio Abbene; Lucio Lo Coco; Alessandra Malato; Rosa Di Trapani; Giorgia Saccullo; Giuseppina Pizzo; Roberto Palazzolo; Rita Barone; Giuseppina Mazzola; Sergio Rizzo; Paolo Ragonese; Paolo Aridon; Vincenzo Abbadessa; Sergio Siragusa
Journal:  Blood Transfus       Date:  2010-07       Impact factor: 3.443

Review 2.  Thrombotic thrombo-cytopenic purpura associated with histamine H2-receptor antagonist therapy.

Authors:  S M Kallal; M Lee
Journal:  West J Med       Date:  1996-05

Review 3.  The impact of HIV-associated anaemia on the incidence of red blood cell transfusion: implications for blood services in HIV-endemic countries.

Authors:  Karin van den Berg; Edward L Murphy; Lelanie Pretorius; Vernon J Louw
Journal:  Transfus Apher Sci       Date:  2014-10-13       Impact factor: 1.764

4.  A second national questionnaire survey of TMA.

Authors:  Naomi Ito-Habe; Hideo Wada; Masanori Matsumoto; Yoshihiro Fujimura; Mitsuru Murata; Takashi Izuno; Minoru Sugita; Yasuo Ikeda
Journal:  Int J Hematol       Date:  2010-06-05       Impact factor: 2.490

Review 5.  Thrombotic thrombocytopenic purpura: survival by "giving a dam".

Authors:  Joel L Moake
Journal:  Trans Am Clin Climatol Assoc       Date:  2004

6.  Intravenous gamma globulin for thrombotic microangiopathy of unknown etiology.

Authors:  Shuichi Ito; Kenichi Okuyama; Tomoko Nakamura; Jun-Ichi Tetanishi; Kazuo Saito; Masanori Matsumoto; Yoshihiro Fujimura; Yukoh Aihara; Shumpei Yokota
Journal:  Pediatr Nephrol       Date:  2006-10-21       Impact factor: 3.714

7.  Thrombotic microangiopathy in the HIV-2-infected macaque.

Authors:  F Eitner; Y Cui; K L Hudkins; A Schmidt; T Birkebak; M B Agy; S L Hu; W R Morton; D M Anderson; C E Alpers
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

Review 8.  The role of splenectomy in the treatment of relapsing thrombotic thrombocytopenic purpura.

Authors:  G A Veltman; A Brand; O C Leeksma; G J ten Bosch; J H van Krieken; E Briët
Journal:  Ann Hematol       Date:  1995-05       Impact factor: 3.673

Review 9.  Pathogenesis of thrombotic microangiopathies.

Authors:  X Long Zheng; J Evan Sadler
Journal:  Annu Rev Pathol       Date:  2008       Impact factor: 23.472

Review 10.  HIV associated thrombotic microangiopathy.

Authors:  S Ahmed; R K Siddiqui; A K Siddiqui; S A Zaidi; J Cervia
Journal:  Postgrad Med J       Date:  2002-09       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.